First‐in‐Human Study of Bamlanivimab in a Randomized Trial of Hospitalized Patients With COVID‐19

Therapeutics for patients hospitalized with coronavirus disease 2019 (COVID‐19) are urgently needed during the pandemic. Bamlanivimab is a potent neutralizing monoclonal antibody that blocks severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) attachment and entry into human cells, which cou...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Peter, Datta, Gourab, Grace Li, Ying, Chien, Jenny, Price, Karen, Chigutsa, Emmanuel, Brown‐Augsburger, Patricia, Poorbaugh, Josh, Fill, Jeffrey, Benschop, Robert J., Rouphael, Nadine, Kay, Ariel, Mulligan, Mark J., Saxena, Amit, Fischer, William A., Dougan, Michael, Klekotka, Paul, Nirula, Ajay, Benson, Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8653186/
https://www.ncbi.nlm.nih.gov/pubmed/34455583
http://dx.doi.org/10.1002/cpt.2405

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8653186/
https://www.ncbi.nlm.nih.gov/pubmed/34455583
http://dx.doi.org/10.1002/cpt.2405

Ejemplares similares